CClinicalTrials.gg
Active, not recruitingNCT05356260Updated Dec 13, 2024

Self-management Compared to Care-as-usual for Men With Lower Urinary Tract Symptoms

An interventional study of URincontrol4men and Care as usual in Lower Urinary Tract Symptoms, sponsored by University Medical Center Groningen. Active, not recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Research question: Does offering an online self-management program lead to more efficient use of care by men with urinary complaints? Hypothesis: Many men with urinary symptoms receive medication from their GP. Advice on how to self-manage complaints is often skipped. This while self-management is effective. By offering self-management instead of visiting a GP the use of care by men with urinary complaints may decrease and treatment may become more efficient.

Study design: Men are randomized to receive either care-as-usual by their GP or the online self-management program. Men will be followed for six months and the cost-effectiveness of the online self-management intervention will be compared to the care-as-usual

Read the detailed description

Rationale: Although self-management can be difficult to implement because it is time consuming to explain, it has proven effective for LUTS. For this reason, we developed an online intervention that can be used at home by men with LUTS, giving tailored advice to each case. Objective: To assess the effectiveness and cost-effectiveness of providing an online personalized self-management program as a first-line intervention to men with lower urinary tract symptoms (LUTS) compared to care as usual (CAU).

Study design: A pragmatic non-inferiority randomized controlled trial in the general population. Study population: Men with LUTS (>18 years of age) who are considering visiting a general practitioner for their complaints.

Intervention: Access to an online program offering personalized selfmanagement advice compared to care as usual Main endpoints: Outcomes will be assessed at 6 weeks, 3 months and 6 months.

02

Conditions studied

  • Lower Urinary Tract Symptoms

Keywords

  • Lower urinary tract symptoms
  • eHealth
  • Self-management
  • Primary care
03

In context

Lower Urinary Tract Symptoms

406 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

This study's enrollment of 175 is above the median of 93 across 260 interventional studies indexed under Lower Urinary Tract Symptoms.

Browse Lower Urinary Tract Symptoms studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Men with lower urinary tract symptoms who are thinking about visiting a GP for their complaints

Exclusion criteria

Exclusion Criteria:

  • Men with complicated LUTS who should seek urgent care, including those with nocturnal incontinence (e.g., chronic urinary retention), the inability to void despite urgency (e.g., acute urinary retention), and with sudden onset or worsening LUTS (e.g., urinary tract infections).
  • Men receiving treatment from a pelvic physiotherapist, GP, or urologist (including at any point in the previous year).
  • Men with a history of prostate cancer, bladder cancer, or urinary tract surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Active comparator
    Care as usual

    CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.

    Other: Care as usual

  • Experimental
    Online self-management intervention

    Participants in the intervention group will be given access to an online self-management program that will be personalized. This program was developed based on the results of a literature search, the opinions of expert Dutch GPs and urologists, and a pilot study in secondary care, with further preliminary testing in primary care. The program consists of nine components: information, pelvic floor exercises, bladder training, sitting voiding position, urethral milking, fluid management, caffeine avoidance, alcohol avoidance, and physical activity increase. Information is presented as text with supportive figures, plus audio (a "read aloud function" for all text) and video fragments to facilitate engagement by men with low literacy levels.

    Device: URincontrol4men

Interventions

  • DeviceURincontrol4men

    The intervention is built as an app

  • OtherCare as usual

    CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.

06

What researchers measure

Primary outcomes

  1. The Patient Global Impression of Improvement (PGI-I)

    The PGII is a single-question global index for change of incontinence symptoms that is rated with a 7-point Likert scale ranging from "very much worse" to "very much better." This variable will be dichotomized into "improved" (scores ≥ "better") and "not improved."

    Time frame: 6 months

Secondary outcomes

  1. International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Module (ICIQ-MLUTS)

    The ICIQ-MLUTS is a questionnaire for evaluating male lower urinary tract symptoms and impact on quality of life. Its has two subscales; voiding symptoms (range 0 -20) and incontinence symptoms (range 0-24) with higher scores indicating more symptoms.

    Time frame: 6 weeks and 6 months

  2. International Prostate Symptom Score Quality of Life (IPSS QoL)

    International Prostate Symptom Score (single item) quality of life. The score ranges from 0 - 6 with a higher score indicating a lower quality of life.

    Time frame: 6 weeks and 6 months

  3. the EuroQol instrument (EQ-5D-5L)

    The EQ-5D-5L is s generic quality of life questionnaire. Utilities can be calculated from this questionnaire with a maximum score of 1 indicating a perfect health state.

    Time frame: 6 weeks and 6 months

  4. iMTA Medical Consumption Questionnaire (iMCQ)

    Costs of medical consumption

    Time frame: 6 months

  5. iMTA Productivity Cost Questionnaire (iPCQ)

    Costs of productivity losses

    Time frame: 6 months

07

Study locations

1 site
  • University Medical Center Groningen
    Groningen, 9713GZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The processed, anonymised data will be made available in DataverseNL and a persistent identifier to a minimal dataset(s) will be given in the publication(s).

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05356260
Lead sponsor
University Medical Center Groningen
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Bekkenbodem4All, Leiden University Medical Center, University of Twente, Isala
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Apr 8, 2022
Primary completion
Dec 5, 2024 (estimated)
Completion
Dec 5, 2024 (estimated)
Last update
Dec 13, 2024

Study contacts

Marco Blanker
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion